This is an outdated version published on 2023-03-28. Read the most recent version.

Management and Treatment of Atopic Dermatitis in Primary Care

Authors

  • Chih-ho Hong, MD, FRCPC Clinical Assistant Professor, University of British Columbia

DOI:

https://doi.org/10.58931/cpct.2023.116

Abstract

Atopic dermatitis (AD) is a chronic, relapsing, and remitting, inflammatory skin disease characterized by erythema, edema, xerosis, erosions/excoriations, oozing and crusting. It typically begins in childhood and often in infancy. The disease can wax and wane and for many patients it becomes less severe or even remits over time. Seasonal variation is common, with most patients experiencing a worsening of symptoms in the wintertime, particularly in Canada.

Author Biography

Chih-ho Hong, MD, FRCPC, Clinical Assistant Professor, University of British Columbia

Dr. Hong is a board certified dermatologist working in Surrey BC. He runs a busy clinic with a focus on cosmetic procedures and clinical trials. He is a Clinical Assistant Professor in the Department of Dermatology and Skin Sciences at UBC. His main areas of interest are psoriasis and eczema. He has been an investigator in over 160 trials of treatments in dermatology and has over 50 peer reviewed publications including recent publications in the Lancet and the New England Journal of Medicine. He has lectured locally, nationally and internationally on dermatology treatments

References

Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. Journal of Cutaneous Medicine and Surgery. 2018 Nov;22(1_suppl):10S-6S.

Asher MI, Rutter CE, Bissell K, Chiang CY, El Sony A, Ellwood E, Ellwood P, García-Marcos L, Marks GB, Morales E, Mortimer K. Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I Cross-sectional study. The Lancet. 2021 Oct 30;398(10311):1569-80.

Weiss ST. Eat dirt—the hygiene hypothesis and allergic diseases. New England Journal of Medicine. 2002 Sep 19;347(12):930-1.

Hill DA, Spergel JM. The atopic march: critical evidence and clinical relevance. Annals of Allergy, Asthma & Immunology. 2018 Feb 1;120(2):131-7.

Kirchhof MG, Landells I, Lynde CW, Gooderham MJ, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section I: pathophysiology of atopic dermatitis and implications for systemic therapy. Journal of Cutaneous Medicine and Surgery. 2018 Nov;22(1_suppl):6S-9S.

Eichenfield LF, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology. 2014;70(2):338-51.

Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB. Consensus conference on pediatric atopic dermatitis. Journal of the American Academy of Dermatology. 2003 Dec 1;49(6):1088-95.

Gooderham M, Lynde CW, Papp K, Bourcier M, Guenther L, Gulliver W, Hong CH, Poulin Y, Sussman G, Vender R. Review of systemic treatment options for adult atopic dermatitis. Journal of Cutaneous Medicine and Surgery. 2017 Jan;21(1):31-9.

Gabros Sarah, Trevor A. Nessel, and Patrick M. Zito. Topical corticosteroids. (2018).

Faergemann J, Christensen O, Sjövall P, Johnsson A, Hersle K, Nordin P, Edmar B, Svensson Å. An open study of efficacy and safety of long‐term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 2000 Sep;14(5):393-6.

Wollenberg A, Reitamo S, Atzori F, Lahfa M, Ruzicka T, Healy E, Giannetti A, Bieber T, Vyas J, Deleuran M, European Tacrolimus Ointment Study Group. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008 Jun;63(6):742-50.

Weidinger S, Baurecht H, Schmitt J. A 5‐year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal. British Journal of Dermatology. 2017; 177(4):999-1003.

https://www.arcutis.com/arcutis-announces-positive-topline-results-from-integument-1-pivotal-phase-3-trial-of-roflumilast-cream-in-atopic-dermatitis-in-adults-and-children-aged-six-years-and-older/

Peppers J, Paller AS, Maeda-Chubachi T, Wu S, Robbins K, Gallagher K, Kraus JE. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. Journal of the American Academy of Dermatology. 2019 Jan 1;80(1):89-98.

Hong C H, Gooderham MJ, Albrecht L, et al. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section V: consensus statements on the assessment and management of adult patients with moderate-to-severe atopic dermatitis. Journal of Cutaneous Medicine and Surgery. 2018;22(1_suppl): 30S-35S

Downloads

Published

2023-03-28

Versions

How to Cite

1.
Hong C- ho. Management and Treatment of Atopic Dermatitis in Primary Care. Can Prim Care Today [Internet]. 2023 Mar. 28 [cited 2024 Dec. 4];1(1):12-7. Available from: https://canadianprimarycaretoday.com/article/view/1-1-2-Hong

Issue

Volume 1, Issue 1, March 2023

Section

Articles

License

Copyright (c) 2023 Canadian Primary Care Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.